Adil Javed, MD, PhD has expertise in autoimmune diseases of the brain and spine, including multiple sclerosis, lupus, Sjögren's disease, and other related connective tissue diseases. He has particular clinical and research interests in neuromyelitis optica (NMO), also known as Devic's disease. In addition, he specializes in nervous system complications of infectious and post-infectious diseases.
Dr. Javed is also a principle investigator in several multiple sclerosis trials. His translational research interests include analyzing brain pathology using new and unconventional magnetic resonance imaging (MRI) techniques.
The University of Chicago Medicine
IL
Fellowship
Yale University School of Medicine
CT
Residency
Evanston Northwestern Hospital
IL
Internship
Southern Illinois University
IL
M.D.
Southern Illinois University
IL
Ph.D.
Validation of retroactively derived T1 relaxation values from 3D T1-weighted images with clinical and MRI measures of disability in multiple sclerosis.
Validation of retroactively derived T1 relaxation values from 3D T1-weighted images with clinical and MRI measures of disability in multiple sclerosis. PLoS One. 2025; 20(5):e0323898.
PMID: 40388456
T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis.
T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis. Neuroradiology. 2024 Oct; 66(10):1709-1719.
PMID: 38880824
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
PMID: 37086634
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study.
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
PMID: 36773543
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
PMID: 36724181
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches.
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. PLoS One. 2022; 17(9):e0274778.
PMID: 36137122
Application of a novel T1 retrospective quantification using internal references (T1-REQUIRE) algorithm to derive quantitative T1 relaxation maps of the brain.
Application of a novel T1 retrospective quantification using internal references (T1-REQUIRE) algorithm to derive quantitative T1 relaxation maps of the brain. Int J Imaging Syst Technol. 2022 Nov; 32(6):1903-1915.
PMID: 36591562
Effect of Deep Brain Stimulation on Cerebellar Tremor Compared to Non-Cerebellar Tremor Using a Wearable Device in a Patient With Multiple Sclerosis: Case Report.
Effect of Deep Brain Stimulation on Cerebellar Tremor Compared to Non-Cerebellar Tremor Using a Wearable Device in a Patient With Multiple Sclerosis: Case Report. Front Hum Neurosci. 2021; 15:754091.
PMID: 35095448
COVID-19 in multiple sclerosis patients and risk factors for severe infection.
COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020 Nov 15; 418:117147.
PMID: 32980780
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2020 Jun 15; 17(1):189.
PMID: 32539719